Viridian Therapeutics logo

Viridian Therapeutics

VRDN | NASDAQ
Chart Builder DCF Calculator
$29.80
-$1.07 (-3.47%)
At close: Nov 16, 2026, 4:00 PM ET
$29.80
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.47%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
48.9
Fundamentals Average
Market Sentiment Bullish
Moat None
Sector Rank #311/1021 (Top 30%)

Key Statistics

Market Data

Market Cap $3.38B
1D Range
29.75 31.37
52W Range
13.30 33.78

Valuation (TTM)

PE -7.70
PB 5.83
EV/EBITDA -6.15

Valuation (NTM)

Forward PE N/A
Forward PEG -15.74
Price Target $39.00
Loading financial charts...

Profile

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclona...

Sector Healthcare
Industry Biotechnology
Employees 252
IPO Date Jun 18, 2014
Fiscal Year January - December

Latest News

Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans Transcript

8 days ago · seekingalpha.com

Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans Transcript
Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing

8 days ago · benzinga.com

Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

8 days ago · businesswire.com

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026

10 days ago · businesswire.com

Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know

11 days ago · zacks.com

Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead

12 days ago · seekingalpha.com

Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call

12 days ago · marketbeat.com

What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates

13 days ago · zacks.com

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

13 days ago · businesswire.com

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$0.81
Beat +20.59%
REV
$25.75M
Beat +445.09%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$39.00
Upside
+30.87%
Buy (9)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.